Brief: Synact Pharma Recieves Pre-IND Response From The U.S. FDA
29/06/2022 17:02
June 29 (Reuters) - SynAct Pharma AB SYNACT.TE :
* SYNACT PHARMA RECIEVES PRE-IND RESPONSE FROM THE US FDA
Source text for Eikon: ID:nWkr8Zf2Tk
Further company coverage: SYNACT.TE
((Reuters.briefs@thomsonreuters.com;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development